読み込み中
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
前日終値
$25.54
−$0.13 · -0.51%
日中の時刻はETです。市場データは遅延する場合があります。
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
日中レンジ
現在 $25.54
52週レンジ
現在 $25.54
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
62
強気
リスク
52
やや高いリスク
モメンタム
55
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
日中レンジ
現在 $25.54
52週レンジ
現在 $25.54
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 389.93万 USD | — | — | — | — |
| 粗利益 | −389.93万 USD | — | — | — | — |
| 研究開発 | 2.25億 USD | 1.09億 USD | 7010.3万 USD | 3619.3万 USD | 2911.1万 USD |
| 販売・一般管理 | 6155.4万 USD | 4941.4万 USD | 3267.2万 USD | 1636.8万 USD | 858.5万 USD |
| 営業費用 | 2.84億 USD | 1.58億 USD | 1.03億 USD | 5256.1万 USD | 3769.6万 USD |
| 受取利息 | 3596.79万 USD | 3603.01万 USD | 1337.94万 USD | 125.55万 USD | 122 USD |
| 支払利息 | — | — | 1339.1万 USD | — | 12.22万 USD |
| 減価償却費と償却費 | 133.3万 USD | 99.2万 USD | 29.5万 USD | 27.7万 USD | 7.2万 USD |
| 営業利益 | −2.88億 USD | −1.58億 USD | −1.03億 USD | −5256.1万 USD | −3769.6万 USD |
| 純利益 | −1.41億 USD | −1.23億 USD | −8962万 USD | −5132.1万 USD | −4000.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB1227.74万0.12%108.2億 USD0.44%$206.49+3.00%
American Century Focused Dynamic Growth ETFFDG331.63万0.81%4.35億 USD0.45%$138.7+1.57%
ALPS Medical Breakthroughs ETFSBIO231.37万1.21%1.91億 USD0.50%$55.04+2.03%
Fidelity Fundamental Small-Mid Cap ETFFFSM224.05万0.14%14.4億 USD0.43%$34.13+0.62%
State Street SPDR Portfolio Emerging Markets ETFSPEM214.72万0.01%175.23億 USD0.07%$52.21+1.32%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM116.23万2.10%5528.53万 USD0.59%$29.6009+1.06%
American Century Mid Cap Growth Impact ETFMID96.02万0.95%1.46億 USD0.45%$72.81+1.30%
TrueShares Technology, AI and Deep Learning ETFLRNZ85.81万1.91%4488.05万 USD0.68%$69.015+2.09%iShares Biotechnology ETFIBBAmerican Century Focused Dynamic Growth ETFFDGALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMState Street SPDR Portfolio Emerging Markets ETFSPEMRoundhill Investments - GLP-1 & Weight Loss ETFOZEMAmerican Century Mid Cap Growth Impact ETFMIDTrueShares Technology, AI and Deep Learning ETFLRNZAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
